

1           **Prevalence of HIV1 Infection and Its Associated Factors among Exposed**  
2                           **Infants at Shegaw Motta General Hospital, Ethiopia**

3   **Destaw Kebede Nigusie<sup>1, 2\*</sup> Fantahun Getaneh Damitew <sup>1</sup>, Kirubel Endalamaw Melsew<sup>1</sup>,**  
4   **Girma Zerefaw <sup>3</sup> , Abebe Feneta Nigusie<sup>4</sup>**

5   1 Department of Diagnostic Medical Laboratory Science at Shegaw Motta General Hospital,  
6   East Gojjam, Motta Town, Ethiopia,

7   2 Department of Bacteriology and Mycology Reference Laboratory, Amhara Public Health  
8   Institute (APHI)- Debre Markos Branch, Debre Markos Town, Ethiopia

9   3 Department of Molecular Biology and Virology Reference Laboratory, Amhara Public Health  
10   Institute (APHI), Bahir Dar Town, Ethiopia

11   4 Department of Medical Laboratory science, College of Medicine and Health science, Debre  
12   Markos University, Debre Markos Town, Ethiopia

13

14   \*Correspondence Author, [amauldestaw@gmail.com](mailto:amauldestaw@gmail.com)

15

16

17

18

19

## 20 Abstract

21 **Background:** Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome is a  
22 leading cause of death and disease burden. Following this, vertical transmission is the main  
23 source of HIV infection on children globally. Morbidity and mortality among HIV-exposed  
24 infants are still the main health challenges in Ethiopia. Therefore, the aim of this study was to  
25 determine the prevalence of HIV1 infection and its associated factors among exposed infants at  
26 Shegaw Motta General Hospital, Ethiopia.

27 **Methods:** Hospital-based cross-sectional study was conducted on exposed infants at Shegaw  
28 Motta General Hospital from September 1, 2022 to July 30, 2023. The consecutive convenience  
29 sampling technique was used to select study participants. Whole blood sample was collected  
30 from mothers and infants. Laboratory tests like early infant diagnosis, cluster of differentiation 4  
31 counts and viral load were performed using standard operating procedure. Then, the data were  
32 entered into EpiData version 3.1 and analyzed by SPSS version 20. Finally, bivariable and  
33 multivariable logistic regressions were carried out to identify factors significantly associated  
34 ( $P < 0.05$ ).

35 **Results:** Out of 155 infants, about 79(50.9%) infants were females and 87(56.1%) was urban  
36 resident. Furthermore, majority of infants were born from mothers who could not able to write  
37 and read 88(56.8%) and maternal ages range from 25-34 years were 138(89.0%). The overall  
38 prevalence of HIV1 infection among exposed infants was 6(3.87%) with (95%CI: 2.9-8.2).  
39 Pregnant women had not antenatal care (AOR=7.281,  $P = 0.001$ ), home delivery (AOR= 3.239,  
40  $P=0.001$ ), maternal not received antiretroviral prophylaxis (AOR = 9.213,  $P= 0.001$ ), infants  
41 not intake nevirapine prophylaxis (AOR=2.560,  $P= 0.007$ ) and maternal high viral load (AOR=  
42 5.120,  $P= 0.004$ ) were the factors associated with HIV infection among exposed infants.

43 **Conclusion:** The HIV1 infection among exposed infants was still high (3.87%). Pregnant  
44 women had not antenatal care follow up, home delivery, maternal high viral load, and not  
45 receiving antiretroviral prophylaxis, infant not intake nevirapine prophylaxis increases the risk  
46 of HIV1 infection. Therefore, health facilities should strictly strengthen the PMTCT service by  
47 providing maternal antiretroviral prophylaxis, infant nevirapine prophylaxis, promoting  
48 antenatal care service, early screening maternal viral load and scale up skilled delivery to  
49 eliminate HIV infection among exposed infants.

50 **Keywords:** HIV infection, associated factors, exposed infants, Ethiopia

## 51 **Introduction**

52 Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) is a  
53 leading cause of death and disease burden [1]. Following this, vertical transmission is the main  
54 source of HIV infection in children with an estimated 2000 vertically-acquired HIV infections  
55 occurring daily in global and mostly in Eastern Europe and Central Asia [2]. However, about  
56 330,000 children were infected with HIV in 2011 globally, with over 90% of these infections  
57 through mother-to-child transmission was illustrating in sub-Sahara Africa [3].

58 Ethiopia is one of these priority countries where every 3 children born to women living with HIV  
59 still gets infected with HIV [4, 5]. So, infants acquire infection with HIV-1 through mother-to-  
60 child transmission (MTCT) of the virus [6]. MTCT of HIV-1 can occur through intrauterine (IU),  
61 at the time of labor and delivery or intra-partum, and postpartum mainly through breastfeeding  
62 [7,8].In addition to prenatal antiretroviral therapies, public health strategies such as prevention of  
63 maternal nipple lesions, mastitis and infant thrush; reduction of breastfeeding duration by all

64 HIV-1-infected mothers; absolute avoidance of breastfeeding by those at high risk, and  
65 prevention of HIV-1 transmission to breastfeeding mothers should be addressed [9].

66 HIV-1 infection in breastfed children born to infected mothers is associated with the presence of  
67 integrated viral deoxy- ribose nucleic acid (DNA) in the mothers' milk cells. IgM and IgA anti-  
68 HIV-1 in breastmilk may protect against postnatal transmission of the virus [10]. However,  
69 international guidance currently states that when replacement feeding is acceptable, feasible,  
70 affordable, sustainable and safe, the avoidance of all breastfeeding by HIV-infected mothers is  
71 recommended [11].

72 Most of the deaths in children with HIV could have been avoided through early infant diagnosis  
73 (EID) and provision of effective care and treatment. Interventions like the use of antiretroviral  
74 (ART) drugs by infected pregnant women, safe delivery practices and safe infant feeding have  
75 helped to reduce the risk of transmission to infants by 40% to 50% [12]. Because of passively  
76 transferred maternal HIV-1 antibodies, which may be present in the child's bloodstream until 18  
77 months of age, antibody tests are not reliable for diagnosing children less than 18 months of age  
78 [12, 13]. Instead, polymerase chain reaction (PCR) such as EID provides a feasible method to  
79 assess prevention of mother- to child transmission (PMTCT) programs and early identify HIV-  
80 infected infants [14] the reason why its high sensitivity and specificity, PCR has been widely  
81 used for diagnosis of HIV amongst exposed infants as well as identification of infection from  
82 birth [15]

83 Ethiopia is among the top ten countries in the world with the highest burden of HIV1 infections  
84 among children [16] with the average number of MTCT of HIV in Ethiopia was 18% [17]. So  
85 that, Child morbidity and mortality among HIV-exposed infants are still the main health

86 challenges in Ethiopia [18]. However, there need a further study beyond HIV 1 and its associated  
87 factors among infants born to HIV positive women. Therefore, the aim of this study was to  
88 determine the prevalence of HIV 1and its associated factors among infants born from HIV  
89 positive mothers at Shegaw Motta General Hospital, Ethiopia.

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

## 105 **Materials and Method**

### 106 **Study design, area and period**

107 Hospital based cross sectional study was conducted at Shegaw Motta General Hospital (SMGH)  
108 which is found in East Gojjam zone, Amhara regional state. Shegaw Motta General Hospital is  
109 found in Amhara region, which is located at a distance of 120 Km from Bahir Dar and 370 Km  
110 away from the capital city of the Ethiopia, Addis Ababa. SMGH has provided service to more  
111 than 1.5 million total populations. Whenever, this study was conducted from September 1, 2022  
112 to July 30, 2023.

### 113 **Study Population and participants**

114 All infants (ages < 12months) born from HIV positive mothers were the study population. While,  
115 all HIV exposed infants attending PMTCT clinic in Shegaw Motta General Hospital and  
116 providing a blood sample during the study period were study participants.

### 117 **Sample size and sampling technique**

118 The sample size was calculated by using single population proportion formula by taking the  
119 prevalence of HIV-positive infants born to HIV-positive mothers, 11.4% pooled prevalence in  
120 Ethiopia [19] using the assumption of 95% confidence level ( $Z = Z_{\alpha/2} = 95\% = 1.96$ ), margin of  
121 error ( $d = 5\% = 0.05$ ), Then, sample size was determined as follows:

122

$$123 \quad N = \frac{(Z_{\alpha/2})^2 p (1-p)}{d^2} = 155$$

124

125 Therefore, the minimum of 155 study participants was selected by consecutive convenience  
126 sampling technique.

## 127 **Eligibility criteria**

128 All infants born to HIV positive mother attending PMTCT clinic at Shegaw Motta General  
129 Hospital were included in this study. While, exposed infants who were critically ill and whose  
130 parents were unwilling to give their consent were excluded from the study.

## 131 **Data collection and processing**

132 The data were collected by trained a midwifery and principal investigator. Thus, socio-  
133 demographic and associated factors were collected by semi-structured pre-tested Amharic  
134 version questionnaire using a face-to-face interview with parents of study participants directly  
135 after obtaining consents. At each data collection spot, sufficient explanation about the aim of the  
136 research was given to the parents before conducting the interview.

## 137 **Blood specimen collection, transportation and storage**

138 A minimum of 100 $\mu$ l whole blood specimen was collected using ethylene diamine tetra acetylene  
139 (EDTA) test tube as per the manufacturer`s instruction at heel or toe site of the infants who born  
140 to HV positive mother [20]. The collected whole blood was transported immediately from  
141 PMTCT clinic to Shegaw Motta General Hospital, Microbiology laboratory for Examination.  
142 Due to the Cepheid was busy by which GeneXpert MTB/RIF tests were done and the sample was  
143 not done immediately, the samples were stored at 2-8 $^{\circ}$ c, 15-30 $^{\circ}$ c and 31-35 $^{\circ}$ c for up to 72, 24 and  
144 8 hours, respectively [21]. Additionally, 5ml of whole blood was collected from mother with  
145 EDTA K3 plasma separating tube (PPT), wait for 4-12 hours and then centrifuged at 3000  
146 rpm for 3 minute to separate the 1-2ml plasma from red blood cells. Such separated  
147 plasma was stored at 2-8 $^{\circ}$ C for a week due to not done immediately. After then, it was

148 transported to Debre Markos Comprehensive specialized hospital (DMCSH), Molecular  
149 biology laboratory at 2-8°C with triple packaging system to determine maternal viral load.

## 150 **Laboratory testing**

### 151 **Early Infant diagnosis (EID) by GeneXpert HIV-1 Qual Assay**

152 In the newly updated algorithm, samples that are nonreactive or indeterminate in the  
153 differentiation assay are to be tested with an HIV-1 nucleic acid amplification (NAAT) test for  
154 resolution. Xpert HIV-1 Qual assay is a new NAAT assay approved for the identification of HIV  
155 infection in whole blood [21].

156 GeneXpert HIV-1Qual assays were conducted according to manufacturer's recommendations.

157 EID could be done by the GeneXpert HIV-1 Qual Assay using GeneXpert system machine  
158 (Cepheid)[22] by trained laboratory personnel during the study period. The GeneXpert® HIV-1

159 Qual is a molecular cartridge-based assay that detects total nucleic acid (DNA and RNA) and  
160 provides a qualitative result (HIV detectable or undetectable) [23]. As such, the GeneXpert HIV

161 Qual cartridge was labeled with the identification collected blood sample. Then after it was  
162 opened and 750 µl of sample reagent was transferred in using provided /inserted pipette in the

163 kit. Mix the whole blood as well by inverting the EDTA tube containing such blood at least  
164 seven times. About 100µl whole blood was transferred immediately using provided pipette in the

165 kit or calibrated automatic pipette in to same sample chamber of GeneXpert HIV Qual cartridge

166 soon after the lid was firmly closed. Finally, the prepared GeneXpert HIV Qual cartridge was run  
167 by starting the test on GeneXpert machine and interpreted the result output as “HIV-1 detected”

168 or “HIV-1 not detected” after 90 minutes [24].



169 **Cluster of differentiation at 4 (CD4) Count**

170 Maternal CD4 was counted using FACS Presto Machine after incubating one drop (40µl) out of  
171 collected 5ml maternal blood for viral load samples on CD4 cartridge for 18 Minute. Then,  
172 assess its association with HIV infection among exposed infants.

173 **Maternal Viral Load determination**

174 5ml of whole blood was collected from mother with EDTA K3 plasma separating tube (PPT),  
175 wait for 4–12hours and then centrifuged at 3000 rpm for 3minute to separate the 1-2ml  
176 plasma from red blood cells. Such separated plasma was stored at 2-8°C for a week due to  
177 not done immediately. After then, it was transported to Debre Markos Comprehensive  
178 specialized hospital, Molecular biology laboratory at 2-8°C with triple packaging system to  
179 determine maternal viral load. Finally, the viral load level was determined by PCR  
180 technique (Roche Diagnostics GmbH, Mannheim, Germany), the high or low viral load results  
181 were recorded and assessed its association with HIV infection to infants.

182 **Quality control**

183 The structured questionnaires were prepared in English and translated into Amharic language  
184 and then back translated to English to check inconsistencies of meaning of words. About 9 (5%)  
185 of structured questionnaire was pretested in Motta health center and training was also provided to  
186 one BSc midwifery how to collect the socio-demographic and clinical data. The expired date on  
187 the GeneXpert HIV-1 Qual cartridges was checked and the GeneXpert system machine (Cepheid)  
188 was calibrated annual regularly. Quality control for CD4 was also done and printed out daily  
189 soon after start up the FACS Presto CD4 Machine and it was cross checked with its standard  
190 reference ranges.

## 191 **Data analysis**

192 Data was entered by EpiData version 3.1 and data analysis was performed using statistical  
193 package for social sciences (SPSS) version 20. The prevalence of HIV-1 was determined by  
194 descriptive statistics. Multivariable logistic regression was done by entering the variables with  
195  $p < 0.2$  in the bivariable logistic regression to identify the factors associated with HIV-1  
196 infection among exposed infants by considering the  $P$  value  $< 0.05$  as a statistically significant  
197 association.

## 198 **Ethical Consideration**

199 Ethical clearance and permission letter were obtained from Shegaw Motta General Hospital  
200 administrative office with reference number (SMGH 534/94/72). Additionally, written consent  
201 was obtained from a parent and/or legal guardian of study participants in accordance with the  
202 Declaration of Helsinki. Furthermore, the participation of study participants was entirely  
203 volunteer based on parents and/or legal guardian and their confidentiality was kept by coding  
204 rather than naming for identification. Finally, all HIV positive infants were linked to ART  
205 clinic at this hospital for further management.

## 206 **Operational definitions**

207 **GeneXpert HIV-1 Qual assays:** GeneXpert® Instrument Systems, is a qualitative in vitro  
208 diagnostic test designed to detect human immunodeficiency virus Type 1 (HIV-1) total nucleic  
209 acids using human venous whole blood and capillary from individuals suspected of HIV-1  
210 infection for infant.

211 **Infant:** infants or babies whose age less than 12 months and cannot produce their own serological  
212 detectable antibodies against HIV.

213 **HIV1 exposed infants:** The infants who born from HIV positive mother or women.

214 **Results**

215 **Socio-demographic characteristics of study participants**

216 A total of 155 infants were recruited to the current study from which almost more than half of  
 217 infants 79(50.9%) were females and the rest males. Furthermore, the majority of 87(56.1%),  
 218 87(56.1%), 123 (79.4%), 138(89.0%) and 148(95.5%) infants were born from mothers who  
 219 could not able to write and read, urban residence, self-employed, ages range from 25-34years  
 220 and married mother, respectively. About 90 (58.1%) infants were less than 6 months in their age  
 221 and the rest 65 (41.9%) was 6- 12months in the current study (Table: 1).

222 **Table 1:** Socio-demographic characteristics of study participants at Shegaw Motta General  
 223 Hospital, 2023

Variable	Categories	Frequency	Percent (%)
Gender of infant	Male	76	49.1
	Female	79	50.9
Residence	Urban	87	56.1
	Rural	68	43.9
Maternal education	Unable to read and write	87	56.1
	Primary & above	68	43.9
Maternal age (in years)	< 25	6	3.9
	25–34	138	89.0
	≥35	11	7.1

Maternal marital status	Not married	7	4.5
	Married	148	95.5
Maternal occupation	Housewife	24	15.4
	Government employee	8	5.2
	Self-employed	123	79.4
Infant age (in months)	<6 months	90	58.1
	6- 12months	65	41.9

224

225

226

### 227 **Prevalence HIV 1 among exposed infants**

228 One hundred fifty-seven HIV-exposed infants were tested for HIV infection by GenXpert HIV1  
229 Qual assay (EID). This study revealed that the overall prevalence of HIV1 infection among  
230 exposed infants was 6 (3.87%) with 95% CI; 2.9 - 8.2 in the current study (Fig 1).

### 231 **Factors Associated with HIV1 infection among exposed infants**

232 According to bivariable analysis, residence, maternal education level, antenatal care (ANC)  
233 follow up, maternal Antiretroviral therapy (ART) enrolment, place of delivery, infant's age at  
234 enrollment, attendant of delivery, maternal Antiretroviral (ARV) prophylaxis, infant nevirapine  
235 (NVP) prophylaxis, maternal CD4+ (cell/mm<sup>3</sup>) and maternal viral load (p-value < 0.2) were  
236 entered to multivariable logistic regression analysis. Regarding to multivariable logistic  
237 regression analysis, pregnant women had not ANC follow up (AOR=7.281, 95% CI: 2.53-  
238 20.96;  $P = 0.001$ ), home delivery ( AOR = 3.239, 95% CI: (1.75-9.19,  $P= 0.001$ ), maternal not

239 received ARV prophylaxis (AOR = 9.213, 95% CI: 2.95-10.11,  $P = 0.001$ ), infant not intake  
 240 NVP prophylaxis (AOR = 2.560, 95% CI: 1.98-10.24,  $P = 0.007$ ) and maternal high viral load  
 241 (>1000 copies) (AOR = 5.120, 95% CI: 2.75-11.18,  $P = 0.004$ ) during pregnancy were the  
 242 identified factors significantly associated with HIV infection among infants born to HIV  
 243 positive mothers. As the result, infants born to HIV positive mother who had not ANC follow  
 244 up, home delivery, maternal not received ARV prophylaxis, infant not intake NVP prophylaxis  
 245 and maternal high viral load (>1000 copies) were 7.281, 3.239, 9.213, 2.560 and 5.120 times  
 246 more likely to be infected by HIV in this study, respectively (Table 2).

247 **Table 2:** Bivariable and multivariable logistic regression analysis of factors associated with  
 248 HIV1 infection among exposed infants at Shegaw Motta General Hospital Town, Ethiopia, 2023

Variables	Categories	HIV1		COR(95%CI) $P$ value	AOR(95%CI)	$P$ value
		Positive N (%)	Negative N(%)			
Gender of infant	Male	2(2.6)	74(97.4)	1		
	Female	4(5.4)	71(94.6)	2.324(0.69-5.61)0.720		
Infant age (in months)	<6 months	6 (6.7)	84 (93.3)	1.653(0.812-7.921)0.431		
	6- 12months	0(0)	65 (100)	1		
Residence	Urban	4(3.4)	83(96.6)	1	1	
	Rural	2(2.9)	66(97.1)	3.12 (1.45-5.11)0.102*	2.51(0.69-4.67)	0.145
Maternal education	Unable read and write	3(3.4)	85(96.6)	1.78(2.14-4.76)0.019*	3.16(0.43-5.89)	0.205
	Primary & above	3(4.5)	64(95.5)	1	1	
Maternal age (in years)	< 25	0 (0)	6 (100)	1		
	25–34	4 (3.0)	131 (97.0)	0.729(0.31-1.73)0.473		
	≥ 35	2 (18.2)	9 (81.8)	1.545(0.47-5.12)0.478		
Maternal marital status	Not married	1(14.3)	6(85.7)	1		
	Married	5 (3.4)	143(96.6)	1.714(0.72-4.11)0.427		

Maternal occupation	Housewife	2(8.3)	22 (91.7)	0.857(0.31-2.43) 0.367		
	Self-employed	3 (2.5)	120 (97.5)	1.6490.418-3.24) 0.771		
	Government employee	1(12.5)	7(87.5)	1		
ANC follow up	Yes	2 (2.7)	73 (97.3)	1	1	
	No	4 (5.0)	76 (95.0)	10.615(4.40-25.61)0.001*	7.281(2.53-20.96)	0.001**
Maternal ART enrolment	Enrolled	2 (1.5)	135 (98.5)	1	1	
	Not enrolled	4 (23.3)	14 (77.7)	16.179(4.58-57.22)0.001*	6.985(0.61-28.91)	0.195
Place of delivery	Home	2(3.9)	49 (96.1)	4.681(1.78-12.29) 0.002*	3.239(1.75-9.19)	0.001**
	Health facility	4 (3.8)	100(96.2)	1	1	
Infant Feeding pattern	EBF	0(0)	23(100)	1		
	ERF	2(3.8)	50(96.2)	2.857(0.91-4.43) 0.367		
	MF	4(5.0)	76(95.0)	1.649(0.518-8.24) 0.571		
Infant's age at enrollment	≤ 6 weeks	2(2.0)	100(98.0)	1	1	
	>6 weeks	4 (7.6)	49 (92.4)	4.681(1.78-12.29) 0.002*	5.219(0.65-14.29)	0.327
Maternal ARV intervention	Before delivery	1(2.6)	38(97.4)	1		
	During/after delivery	2(2.2)	87(97.8)	1.857 (0.31-6.43) 0.367		
	No	3 (11.1)	24(88.9)	4.649(0.418-7.24) 0.771		
Attendant of delivery	TBA	3(2.9)	99(97.1)	4.381(1.68-11.29) 0.001*	4.239(0.75-9.19)	0.512
	Skilled delivery	3 (5.7)	50 (94.3)	1	1	
Maternal ARV prophylaxis	Not Received	4(11.1)	32(88.9)	5.418(2.37-12.41) 0.001*	9.213(2.95-10.11)	0.001**
	Received	2(1.7)	117 (98.3)	1	1	
Infant NVP prophylaxis	Yes	2(2.2)	90(97.8)	1	1	
	No	4(6.4)	59(93.6)	4.681(1.78-12.29) 0.002*	2.560(1.98-10.24)	0.007**
Maternal CD4+ (cell/mm <sup>3</sup> )	< 200	5(31.2)	11(68.8)	1	1	
	≥ 200	1(0.7)	138 (99.3)	5.418(2.37-12.41) 0.001*	9.213(0.95-10.11)	0.354
Maternal viral load	<1000copies (Low)	2(1.4)	139(98.6)	1		
	≥ 1000 copies)(High)	4 (28.6)	10(71.4)	4.681(1.78-12.29) 0.002*	5.120(2.75-11.18)	0.004**

249 Key: \* = variables entered to multivariate regression (P- value < 0.2), \*\* = statistical significant association ;ANC: Antenatal care;  
 250 AOR: Adjusted odd ratio; ART: antiretroviral therapy; ARV: Anti-retroviral; CD4- cluster of differentiation -4 ; CI: confidence  
 251 interval ,COR: crude odd ratio: EBF: exclusive breast feeding ; HIV: human immunodeficiency, MF: mixed feeding; NVP:  
 252 Nevirapine , TBA: Traditional birth attendant

## 253 Discussion

254 The prevalence of HIV1 infection on infants born from HIV positive mothers in the current study  
255 was 3.87%. This finding was in line with studies conducted in various parts of Ethiopia like in  
256 Dessie Town Public Health Facilities 3.8% [25], Pastoralist Health Facilities, South Omo Zone  
257 5.3% [26], East and West Gojjam Zone 5.9% [27] and University of Gondar Specialized Hospital  
258 5.5% [28], East Africa 7.68% (29) and Kenya 3.3% [30].

259 The current prevalence of HIV1 infection was lower than 11.4% pooled prevalence in Ethiopia  
260 [19], 9% in Sidama [31], 10.1% in Amhara Region [32] and 9.9% in Bahir Dar city public health  
261 facilities [33]. This difference might be due to the variation of ART and PMCT follow up,  
262 awareness to HIV, policies, and strategies on HIV control and prevention, methodology and  
263 sample size. In contrast, it was slightly higher than 1.5%, 1.6%, 2.7%, and 2.1%, compared to the  
264 study conducted in France [34], Ukraine [35], Rwanda [36] and Tigray regional state, Northern  
265 Ethiopia [37], respectively. This difference might be due to high coverage of PMTCT  
266 interventions in developed countries and limited access, lack of awareness, poor quality of  
267 service in developing countries including Ethiopia.

268 Regarding to multivariable logistic regression analysis in the current study, mothers had not  
269 ANC follow up (AOR=7.281, 95% CI: 2.53-20.96;  $P = 0.001$ ) was significantly associated with  
270 MTCT of HIV1. Meanwhile, mothers who did not attend ANC follow up were 7.281 times more  
271 likely to transmit the virus to their infants than mothers who had ANC visit. This finding was  
272 agreed with the study conducted in Rwanda [38], Ethiopia [39], Gondar city health institutions,  
273 Northwest Ethiopia [40] and public health facilities in Dessie town [41]. Similarly, home delivery  
274 (AOR = 3.239, 95% CI: (1.75-9.19,  $P = 0.001$ ) was also a factor significantly associated with

275 MTCT of HIV1 infection. Thus, infants born at home had a 3.239 times greater chance of  
276 contracting the virus than those born in health facilities. This finding was concordant with the  
277 study illustrated in East Africa [42], rural Uganda [43], South west Ethiopia [44], Dire Dawa  
278 [45], southern Ethiopia [46], Northwest Ethiopia [47], Gondar city health institutions [40], South  
279 Gondar zone [48] and Bahir Dar administration [49]. This might be due to HIV testing for  
280 mothers with unknown HIV status who delivered at health facility and immediate ARV  
281 intervention for mothers and their infants if the test was positive. In addition, safe delivery  
282 practice and appropriate post-natal care during health facility delivery might support this  
283 significant association.

284 On the other hand, absence of maternal intake ARV prophylaxis (AOR = 9.213, 95% CI: 2.95-  
285 10.11,  $P = 0.001$ ) was 9.213 times more likely to born HIV positive infants compared to those  
286 received ARV prophylaxis. A finding was in line with studies conducted in Vietnam [50], East  
287 Africa [42], Uganda [43], Northwest Ethiopia [47], Ethiopia such as Mekele city [51], health  
288 facilities of North Wollo Zone [52], Bahir Dar administration [49]. This might be as a result of  
289 maternal ARV drug intake causing the reduction of maternal viral load and reduced risk of viral  
290 transmission to their infants. Furthermore, infants not intake NVP prophylaxis (AOR = 2.560,  
291 95% CI: 1.98-10.24,  $P = 0.007$ ) were 2.560 times more likely to be HIV positive as compared to  
292 infants received NVP prophylaxis at birth according to this study. Such findings were agreed  
293 with the previous studies reported in Brazil [53], Uganda (54), Dire Dawa [45], southern  
294 Ethiopia [55] and Ethiopian Public Health Institute [56, 57]. This might be due to the viral  
295 suppression effect of NVP, which is a non-nucleoside reverse transcriptase inhibitor, by binding  
296 to reverse transcriptase, thereby blocking RNA and DNA dependent DNA polymerase actions  
297 including HIV replication.



298 Finally, maternal high viral load (>1000 copies) (AOR = 5.120, 95% CI: 2.75-11.18,  $P = 0.004$ )  
299 during pregnancy were the factors significantly associated with HIV infection among exposed  
300 infants by which infants from high maternal viral load were 5.120times more likely to be  
301 infected by HIV than infants born from low maternal viral load. The findings were concordant  
302 with a study carried out in India [58], Philadelphia [59], Uganda (54), Rwanda [38], Gaza  
303 Province—Mozambique (60), northeast South Africa [61]. This might be due to high viral load  
304 concentration could compromise the maternal immune system and leads to vertical  
305 transmission of HIV to infants.

## 306 **Conclusion**

307 The prevalence of HIV1 infection among exposed infants born to HIV positive mothers was still  
308 high (3.87%). Pregnant women had not ANC visits, home delivery, Absence of ARV  
309 prophylaxis, infants not intake NVP prophylaxis, and maternal high viral load increases HIV  
310 infection among exposed infants. Therefore, health facilities should strictly strengthen the  
311 PMTCT service by providing maternal ARV prophylaxis, infant NVP prophylaxis, promote  
312 ANC service, early screening maternal viral load and scale up skilled delivery to eliminate  
313 HIV infection among exposed infants.

## 314 **Abbreviations**

315 AOR—adjusted odd ratio, ART- Antiretroviral therapy, ARV-antiretroviral, ANC- Antenatal  
316 Care, COR- Crude odd ratio, DNA- Deoxy-ribose nucleicacid, EDTA- ethylenediamine tetra  
317 acetylene, EID- early infant diagnosis, HIV- Human immunodeficiency virus, NAAT- nucleic

318 acid amplification, NVP-nevirapine, PCR- polymerase chain reaction, PMTCT - prevention of  
319 mother- to child transmission, MTCT- mother to child transmission, RNA- ribose nucleic acid

## 320 **Acknowledgments**

321 The authors would like to thank administration of Shegaw Motta General Hospital for providing  
322 a permission to conduct this study. By the next, we would like to acknowledge Molecular  
323 biology laboratory of Debre Markos comprehensive specialized hospital (DMCSH) including its  
324 laboratory staffs that did the viral load of referred plasma sample. We would also like to thank all  
325 laboratory staffs in this hospital, study participants, and data collectors for their unreserved  
326 efforts and willingness to participate in this study.

## 327 **Authors Contribution**

328 **Conceptualization:** Destaw Kebede Nigusie, Fantahun Getaneh Damitew,

329 **Data curation:** Fantahun Getaneh Damitew, Kirubel Endalamaw Melsew

330 **Formal analysis:** Destaw Kebede Nigusie, Melsew , Girma Zerefaw, Abebe Fenta Nigusie :

331 **Investigation:** Destaw Kebede Nigusie, Fantahun Getaneh Damitew, Kirubel Endalamaw  
332 Melsew , Girma Zerefaw, Abebe Fenta Nigusie

333 **Methodology:** Kirubel Endalamaw Melsew, Girma Zerefaw, Abebe Fenta Nigusie

334 **Resources:** Destaw Kebede Nigusie and Fantahun Getaneh Damitew

335 **Supervision:**, Girma Zerefaw Abay, and Abebe Fenta Nigusie

336 **Visualization:** Fantahun Getaneh Damitew, Kirubel Endalamaw

337 **Writing – Original Draft Preparation:** Destaw Kebede Nigusie, Fantahun Getaneh Damitew,

338 **Writing – Review & Editing:** Girma Zerefaw Abay, and Abebe Fenta Nigusie

## 339 **References**

- 340 1. Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, Charlson F, Davis  
341 A, Degenhardt L, Dicker D, Duan L. Global, regional, and national incidence,  
342 prevalence, and years lived with disability for 301 acute and chronic diseases and injuries  
343 in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease  
344 Study 2013. *The lancet*. 2015 Aug 22;386(9995):743-800.
- 345 2. UNAIDS World Health Organization. AIDS epidemic update: December 2009. WHO  
346 Regional Office Europe; 2010 Mar 24, 1-99.
- 347 3. UNAIDS U. Countdown to ZERO: global plan towards the elimination of new HIV  
348 infections among children by 2015 and keeping their mother alive. UNAIDS;  
349 2011. [http://library.tacaids.go.tz/bitstream/handle/123456789/68/Global-Plan-  
350 Elimination-HIV-Children%202011.pdf?sequence=1&isAllowed=y](http://library.tacaids.go.tz/bitstream/handle/123456789/68/Global-Plan-Elimination-HIV-Children%202011.pdf?sequence=1&isAllowed=y)
- 351 4. Newman Owiredu M, Newman L, Nzomo T, ConomboKafando G, Sanni S, Shaffer N,  
352 Bucagu M, Peeling R, Mark J, DiopToure I. Elimination of mother-to-child transmission  
353 of HIV and syphilis: A dual approach in the African Region to improve quality of  
354 antenatal care and integrated disease control. *International Journal of Gynecology &  
355 Obstetrics*. 2015 Jun;130:S27-31.
- 356 5. Berhan Z, Abebe F, Gedefaw M, Tesfa M. Prevalence of HIV and associated factors  
357 among infants born to HIV positive women in Amhara Region, Ethiopia. *International  
358 journal of clinical medicine*. 2014 Apr 17;2014.
- 359 6. Newell ML. Current issues in the prevention of mother-to-child transmission of HIV-1  
360 infection. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2006 Jan  
361 1;100(1):1-5.

- 362 7. Read DJ, Breastfeeding and HIV International Transmission Study Groupa. Late  
363 postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-  
364 analysis. *The Journal of infectious diseases*. 2004 Jun 15;189(12):2154-66.
- 365 8. Zijenah LS, Bandason T, Bara W, Chipiti MM, Katzenstein DA. Mother-to-child  
366 transmission of HIV-1 and infant mortality in the first six months of life, in the era of  
367 Option B Plus combination antiretroviral therapy. *International Journal of Infectious*  
368 *Diseases*. 2021 Jun 21.
- 369 9. Embree JE, Njenga S, Datta P, Nagelkerke NJ, Ndinya-Achola JO, Mohammed Z,  
370 Ramdahin S, Bwayo JJ, Plummer FA. Risk factors for postnatal mother-child  
371 transmission of HIV-1. *Aids*. 2000 Nov 10;14(16):2535-41.
- 372 10. Van de Perre P, Simonon A, Karita E, Butera JB, Hitimana DG, Mukamabano B, Van  
373 Goethem C, Lepage P, Dabis F, Msellati P. Infective and anti-infective properties of  
374 breastmilk from HIV-1-infected women. *The Lancet*. 1993 Apr 10;341(8850):914-8.
- 375 11. World Health Organization (WHO). New data on the prevention of mother-to-child  
376 transmission of HIV and their policy implications: conclusions and recommendations:  
377 WHO Technical consultation on behalf of the UNFPA/UNICEF/WHO/UNAIDS Inter-  
378 Agency Task Team on Mother-to-Child Transmission of HIV, Geneva, 11-13 October  
379 2000. World Health Organization; 2001.
- 380 12. Read JS, Committee on Pediatric AIDS. Diagnosis of HIV-1 infection in children  
381 younger than 18 months in the United States. *Pediatrics*. 2007 Dec;120(6):e1547-62.
- 382 13. World Health Organization. Manual on pediatric HIV care and treatment for district  
383 hospitals: addendum to the Pocket book of hospital care of  
384 children. [https://apps.who.int/iris/bitstream/handle/10665/44511/9789241501026\\_eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/44511/9789241501026_eng.pdf)

- 385 14. Creek T, Tanuri A, Smith M, Seipone K, Smit M, Legwaila K, Motswere C, Maruping  
386 M, Nkoane T, Ntummy R, Bile E. Early diagnosis of human immunodeficiency virus in  
387 infants using polymerase chain reaction on dried blood spots in Botswana's national  
388 program for prevention of mother-to-child transmission. *The Pediatric infectious disease*  
389 *journal*. 2008 Jan 1;27(1):22-6.
- 390 15. Fonjungo PN, Mekonen T, Mengistu Y, Kebede Y, Kenyon TA, Girma M, Tegbaru B,  
391 Tibesso G, Ayana G, Abebe A, Messele T. Field expansion of DNA polymerase chain  
392 reaction for early infant diagnosis of HIV-1: the Ethiopian experience: lessons from the  
393 field. *African journal of laboratory medicine*. 2013 Jan 1;2(1):1-7.
- 394 16. Yitayew YA, Bekele DM, Demissie BW, Menji ZA. Mother to child transmission of HIV  
395 and associated factors among HIV exposed infants at public health facilities, Dessie  
396 Town, Ethiopia. *Hiv/aids (Auckland, NZ)*. 2019;11:343.
- 397 17. Tadele T, Tamiso A, Tadele T. Incidences and predictors of HIV positivity among infants  
398 who born from HIV positive mother who have follow up at two hospitals of southern  
399 Ethiopia, 2014. *Sci J Public Health*. 2014 Sep 1;2(5):431-9.
- 400 18. Kassie DG, Bogale WA, Addisu A. The prevalence of HIV-positive infants born to HIV-  
401 positive mothers attended at the University of Gondar Specialized Hospital Anti-  
402 Retroviral Therapy Services, Northwest Ethiopia, 2018. *HIV/AIDS (Auckland, NZ)*.  
403 2020;12:135.
- 404 19. Endalamaw A, Demsie A, Eshetie S, Habtewold TD. A systematic review and meta-  
405 analysis of vertical transmission route of HIV in Ethiopia. *BMC infectious diseases*. 2018  
406 Dec;18(1):1-1.

- 407 20. Mazanderani AH, Moyo F, Kufa T, Maritz J, Sherman GG. Differentiating clearly  
408 positive from indeterminate results: A review of irreproducible HIV-1 PCR positive  
409 samples from South Africa's Early Infant Diagnosis Program, 2010–2015. *Diagnostic*  
410 *microbiology and infectious disease*. 2018 Jul 1;91(3):248-55.
- 411 21. Michaeli M, Wax M, Gozlan Y, Rakovsky A, Mendelson E, Mor O. Evaluation of Xpert  
412 HIV-1 Qual assay for resolution of HIV-1 infection in samples with negative or  
413 indeterminate Geenius HIV-1/2 results. *Journal of Clinical Virology*. 2016 Mar 1; 76:1-3.
- 414 22. Opollo VS, Nikuze A, Ben-Farhat J, Anyango E, Humwa F, Oyaro B, Wanjala S,  
415 Omwoyo W, Majiwa M, Akelo V, Zeh C. Field evaluation of near point of care Cepheid  
416 GeneXpert HIV-1 Qual for early infant diagnosis. *PloS one*. 2018 Dec 27;13(12):  
417 e0209778.
- 418 23. Garrett NJ, Drain P, Werner L, Samsunder N, Karim SS. Diagnostic accuracy of the  
419 point-of-care Xpert® HIV-1 viral load assay in a South African HIV clinic. *Journal of*  
420 *acquired immune deficiency syndromes (1999)*. 2016 Jun 1;72(2):e45.
- 421 24. Murtagh MM. Molecular Diagnostics for Use in HIV/AIDS Care and Treatment in  
422 Resource-Limited Settings. *Molecular Microbiology: Diagnostic Principles and Practice*.  
423 2016 Apr 28:580-8.
- 424 25. Yitayew YA, Bekele DM, Demissie BW, Menji ZA. Mother to child transmission of HIV  
425 and associated factors among HIV exposed infants at public health facilities, Dessie  
426 Town, Ethiopia. *Hiv/aids (Auckland, NZ)*. 2019; 11:343.
- 427 26. Tadewos K, Adimasu M, Tachbele E. Mother-to-Child Transmission of HIV and  
428 Associated Factors Among Exposed Infants in Pastoralist Health Facilities, South Omo

- 429           Zone, Ethiopia, 2020–A Retrospective Cross-Sectional Study. *HIV/AIDS* (Auckland,  
430           NZ). 2021; 13:1015.
- 431           27. Moges NA, Kassa GM, Boneya DJ. Rate of HIV transmission and associated factors  
432           among HIV-exposed infants in selected health facilities of East and West Gojjam Zones,  
433           Northwest Ethiopia; retrospective cohort study. *BMC infectious diseases*. 2017  
434           Dec;17(1):1-0.
- 435           28. Kassie DG, Bogale WA, Addisu A. The prevalence of HIV-positive infants born to HIV-  
436           positive mothers attended at the University of Gondar Specialized Hospital Anti-  
437           Retroviral Therapy Services, Northwest Ethiopia, 2018. *HIV/AIDS* (Auckland, NZ).  
438           2020;12:135.
- 439           29. Amare Belachew , Tilahun Tewabe and GizatAbinetMalede. Prevalence of vertical HIV  
440           infection and its riskfactors among HIV-exposed infants in East Africa. *Tropical Medicine*  
441           and Health.2020; 48:85
- 442           30. Opollo VS, Nikuze A, Ben-Farhat J, Anyango E, Humwa F, Oyaro B, Wanjala S,  
443           Omwoyo W, Majiwa M, Akelo V, Zeh C. Field evaluation of near point of care Cepheid  
444           GeneXpert HIV-1 Qual for early infant diagnosis. *PloS one*. 2018 Dec  
445           27;13(12):e0209778.
- 446           31. Yosef Y, Tebeje B, Joseph J, Abeje S. HIV Sero Status and Associated Factors Among  
447           HIV-Exposed Infants’ in Selected Health Facilities in Sidama Zone, Southern Ethiopia.  
448           *Journal of Family Medicine and Health Care*. 2020 Jun 10;6(3):70-7.
- 449           32. Berhan Z, Abebe F, Gedefaw M, Tesfa M. Prevalence of HIV and associated factors  
450           among infants born to HIV positive women in Amhara Region, Ethiopia. *International*  
451           *journal of clinical medicine*. 2014 Apr 17;2014.

- 452 33. Birhanu M, Ergetie T, Tenna T, Ayana T, Dessie W, Belay W. Maternal Educational  
453 Level Determine Mother-to-child Transmission of HIV Among HIV-exposed Infants in  
454 Governmental Health Facility of Bahir Dar City, Northwest Ethiopia.
- 455 34. Tubiana R, Le Chenadec J, Rouzioux C, Mandelbrot L, Hamrene K, Dollfus C, Faye A,  
456 Delaugerre C, Blanche S, Warszawski J. Factors associated with mother-to-child  
457 transmission of HIV-1 despite a maternal viral load < 500 copies/ml at delivery: a case-  
458 control study nested in the French perinatal cohort (EPF-ANRS CO1). *Clin Infect Dis*.  
459 2010;50(4):585–96.
- 460 35. Bailey H, Semenenko I, Pilipenko T, Malyuta R, Thorne C. Ukraine European  
461 collaborative study group: factors associated with abandonment of infants born to HIV-  
462 positive women: results from a Ukrainian birth cohort. *AIDS Care*. 2010;22(12):1439–  
463 48.
- 464 36. Nsengimana B, Nkurunziza F, Ntaganira WM, Uzayisenga R, Rutayisire G. HIV  
465 Prevalence and risk factors for infants born to mothers on ARV treatment at  
466 CHUB/Rwanda. <https://doi.org/10.20944/preprints202109.0015.v1>
- 467 37. Desta ML, Saravanan M, Hilekiros H, Kahsay AG, Mohamed NF, Gezahegn AA, Lopes  
468 BS. HIV prevalence and risk factors in infants born to HIV positive mothers, measured  
469 by dried blood spot real-time PCR assay in Tigray, Northern Ethiopia. *BMC pediatrics*.  
470 2019 Dec;19(1):1-8.
- 471 38. Bernard Nsengimana, Francois Nkurunziza, Wivine M Ntaganira, Ruth Uzayisenga and  
472 Gad Rutayisire. HIV Prevalence and risk factors for infants born to mothers on ARV  
473 treatment at CHUB/Rwanda. *Preprints*, 2021;01(09);1-13.  
474 <https://doi.org/10.20944/preprints202109.0015.v1>




- 475 39. Kassie SY, Chereka AA, Damtie Y. Systematic review and meta-analysis of knowledge  
476 on PMTCT of HIV/AIDS and Association factors among reproductive age women in  
477 Ethiopia, 2022. *BMC Infectious Diseases*. 2023 Jul 25;23(1):491.
- 478 40. Tiruneh GA, Dagnez EZ. Prevalence of HIV infection and associated factors among  
479 infants born to HIV-positive mothers in health institutions, northwest Ethiopia, 2021.  
480 *Women's Health*. 2022 Aug;18:17455057221117407.
- 481 41. Yibeltal Asmamaw Yitayew, Daniel Mengistu Bekele ,BirhanuWondimeneh  
482 Demissie andZelege Argaw Menji. Mother to Child Transmission of HIV and Associated  
483 Factors Among HIV Exposed Infants at Public Health Facilities, Dessie Town,  
484 Ethiopia.2019;11 :343–350
- 485 42. Belachew A, Tewabe T, Malede GA. Prevalence of vertical HIV infection and its risk  
486 factors among HIV exposed infants in East Africa: a systematic review and meta-  
487 analysis. *Tropical Medicine and Health*. 2020 Dec;48:1-1.
- 488 43. Kahungu MM, Kiwanuka J, Kaharuza F, Wanyenze RK. Factors associated with HIV  
489 positive sero-status among exposed infants attending care at health facilities: a cross  
490 sectional study in rural Uganda. *BMC public health*. 2018 Dec; 18:1-1.
- 491 44. TAD BB, Sisay K, Gurmessa A, Seyoum D, Tadesse M. Mother tochild HIV  
492 transmission and its predictors among HIV-exposedinfants: a retrospective follow-up  
493 study in Southwest Ethiopia.*J AIDS Clin Res*. 2016;7(9):1–7.
- 494 45. Fisseha W, Damtew B. Mother-to-child transmission of HIV infectionand its  
495 determinants among exposed infants on care and follow-up inDire Dawa City, Eastern  
496 Ethiopia.*AIDS Res Treat*. 2016; 2016:6.

- 497 46. Hussen R, Zenebe WA, Mamo TT, Shaka MF. Determinants of HIV infection among  
498 children born from mothers on prevention of mother to child transmission programme of  
499 HIV in southern Ethiopia: a case-control study. *BMJ open*. 2022 Feb 1;12(2):e048491
- 500 47. Tsehay AK. Risk of HIV and associated factors among infants born to HIV-positive  
501 women in northwest Ethiopia. *Ethiopian Journal of Health Development*. 2019;33(1).
- 502 48. Digsu M. Mother - to - child transmission of HIV - and its predictors among HIV -  
503 exposed infants at a PMTCT clinic in Northwest Ethiopia. *BioMed Center*. 2013; 13:398.
- 504 49. Tsehay AK. Factors associated with HIV-positive sero-status among exposed infants  
505 attending care at health facilities in Bahir Dar administration, Ethiopia: evidence from  
506 medical records. *Cogent Medicine*. 2019 Jan 1;6(1):1623754
- 507 50. Nguyen RN, Ton QC, Tran QH, Nguyen TK. Mother-to-child transmission of HIV and  
508 its predictors among HIV-exposed infants at an outpatient clinic for HIV/AIDS in  
509 Vietnam. *HIV/AIDS-Research and Palliative Care*. 2020 Jul 15:253-61.
- 510 51. Ebuy H, Bekele A, Redae G. HIV testing, test results and factors influencing among  
511 infants born to HIV positive mothers in public hospitals of Mekelle City, North Ethiopia:  
512 a cross-sectional study. *BMC Infectious Diseases*. 2020 Dec; 20:1-0.
- 513 52. Alachew Y, Ejigu T, Mulugeta Y, Ashagrea M. Determinants of Mother to Child  
514 Transmission of HIV Among Infants Born from HIV Positive Women in North  
515 Wollo Zone, North East Ethiopia: 2018, Case Control Study. *J Aids HIV Inf*. 2019; 5(1):  
516 102
- 517 53. Ligia MD, de Lemos JL, Rutherford GW, et al. Maternal risk factors for HIV infection in  
518 infants in northeastern Brazil. *Int J Inf Dis*. 2013; 17:913-918.

- 519 54. Kasozi GK, Robert A. Risk factors associated with HIV infection among infants below  
520 24 months born to HIV positive mothers. *IntJr of HIV/AIDS PrEdu and Beha Sc.*  
521 2017;3(10.11648).
- 522 55. Tariku Tadele AT, Tadele T. Incidences and predictors of HIV positivity among infants  
523 who born from HIV positive mother who havefollow up at two hospitals of southern  
524 Ethiopia.*Sci J Public Health.*2014;2(5):431–439
- 525 56. Gutema G, Tola HH, Fikadu D, Leta D, Bejiga B, Tura JB, Abdella S, Mamo H.  
526 Positivity rate, trend and associated risk factors of mother-to-child transmission of HIV  
527 among HIV-exposed infants. *BMC pediatrics.* 2023 Jun 6;23(1):283.
- 528 57. Gutema G, Tola HH, Fikadu D, Leta D, Bejiga B, Tura JB, Abdella S, Mamo H.  
529 Positivity rate, trend and associated risk factors of mother-to-child transmission of HIV  
530 among HIV-exposed infants. *BMC pediatrics.* 2023 Jun 6;23(1):283.
- 531 58. Bardeskar NS, Ahir-Bist SP, Mehta PR, Samant-Mavani P, Nanavati R, Mania-Pramanik  
532 J. Anti-retroviral therapy failure in HIV-1 infected pregnant women and its associated  
533 risk of HIV transmission. *Archives of Gynecology and Obstetrics.* 2020 Nov;302:1229-  
534 35.
- 535 59. Momplaisir FM, Nassau T, Moore K, Grayhack C, Njoroge WF, Roux AV, Brady KA.  
536 Association of adverse neighborhood exposures with HIV viral load in pregnant women  
537 at delivery. *JAMA Network Open.* 2020 Nov 2;3(11):e2024577-.
- 538 60. Osório D, Munyangaju I, Nacarapa E, Muhiwa A, Nhangave AV, Ramos JM. Mother-to-  
539 child transmission of HIV infection and its associated factors in the district of Bilene,  
540 Gaza Province—Mozambique. *PLoS One.* 2021 Dec 10;16(12):e0260941.

- 541 61. Ngandu NK, Lombard CJ, Mbira TE, Puren A, Waitt C, Prendergast AJ, Tylleskär T,  
542 Van de Perre P, Goga AE. HIV viral load non-suppression and associated factors among  
543 pregnant and postpartum women in rural northeastern South Africa: a cross-sectional  
544 survey. *BMJ open*. 2022 Mar 1;12(3):e058347  
545  
546  
547



**Figure1:** EID positive and negative for HIV1 among exposed infants at Shegaw Motta General Hospital, 2023